The Readout Loud
Episode 205: An ominous biotech deal, vaccines for kids, & 'breakthrough' devices
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Can buyouts be bad news? Why can't Novavax meet a deadline? And what does "breakthrough" actually mean? First, we delve into why the latest big biotech acquisition has ominous implications for the downtrodden sector. Then, STAT's Mario Aguilar joins us to explain how a well-intentioned FDA program is benefiting companies over patients. We also discuss the latest pandemic news, including the ongoing debate over boosters and yet another delay for Novavax.